Skip to main content
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. — Investor Relations & Filings

Ticker · CTMX ISIN · US23284F1057 LEI · 5493004VW2FW0QLL3345 US Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2024-05-17 Director's Dealing
Country US United States of America
Listing US CTMX

About CytomX Therapeutics, Inc.

https://cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company is developing a novel class of antibody therapeutics based on its proprietary Probody® platform. This technology creates masked, conditionally activated biologics designed to be activated specifically within the tumor microenvironment. The goal of this approach is to localize therapeutic activity to the tumor, thereby creating more potent and less toxic treatments for cancer patients. CytomX is advancing a pipeline of Probody drug candidates through its own research and strategic partnerships to address various cancer types.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-05-17 English
Director's Dealing 2024
Director's Dealing
2024-05-17 English
Director's Dealing 2024
Director's Dealing
2024-05-17 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated May 15, 2024. It includes details about an amendment to the company's certificate of incorporation to increase authorized shares, and the results of the 2024 Annual Meeting of Stockholders, including voting results on several proposals. The document primarily reports the official voting results from the shareholder meeting. It does not contain financial statements or detailed financial analysis, nor is it a proxy statement or a full annual report. The presence of detailed voting results and the description of proposals voted on clearly indicate this is a Declaration of Voting Results & Voting Rights Announcement filing. The document length (5964 characters) and content confirm it is not merely an announcement of a report but the actual voting results report.
2024-05-17 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-05-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 8, 2024, for CytomX Therapeutics, Inc. It includes a press release about initial clinical study data and does not contain comprehensive financial statements or detailed financial analysis. The length is 2949 characters, which is relatively short and consistent with a current report announcing an event rather than a full financial report. The document does not fit categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is a regulatory filing reporting a specific event (clinical study data release) and includes a press release as an exhibit. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2024-05-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.